Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.35 |
| ▸ | GLP1R | P43220 | 4/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26133563 | 0.86 | NOS3 (0.41) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL26133569 | 0.86 | NOS3 (0.41) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL22107830 | 0.85 | TSHR (0.41) | TSHR | |
| SCHEMBL25841802 | 0.85 | GLP1R (0.43) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL15483719 | 0.84 | OTC (0.50) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL15618211 | 0.81 | OTC (0.49) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL25360834 | 0.80 | NOS3 (0.40) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL25360824 | 0.80 | NOS3 (0.40) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL16447237 | 0.79 | NOD1 (0.49) | NOS2NOS3NOS1OTCNOD1 | |
| SCHEMBL16447017 | 0.79 | NOS3 (0.42) | NOS2NOS3NOS1OTCNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | BATTELLE MEMORIAL INSTITUTE (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190100792-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | BATTELLE MEMORIAL INSTITUTE | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345950-B2 | Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same | CYP2E1, CYP1A1, CYP7A1 | NOS2 2043/4885NOS3 2319/4885NOS1 2092/4885 |
| US-20190100792-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | CYP2E1, CYP1A1, CYP7A1 | NOS2 2043/4885NOS3 2319/4885NOS1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.